ClinicalTrials.gg
RecruitingNCT07386015Updated Mar 10, 2026

Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)

An observational study in Freezing of Gait, Parkinson's Disease and Parkinsonism, sponsored by Tianjin Huanhu Hospital. Recruiting at 1 site in China. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Tianjin Huanhu Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
16th of 68
700 · median 215
Started
2026
with 40 others
Observational
68 of 279
34 open now
Primary completion
2029-12
later than 128 of 134 live
Registered
237th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 16th largest by planned enrollment of the 68 observational ones that give a count, is one of 41 that started in 2026, is one of 68 observational ones, reaches primary completion later than 128 of the 134 other live ones, and was the 237th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

122 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, observational cohort (patient registry) designed to better understand freezing of gait (FOG), a disabling walking problem that can occur in Parkinson's disease and other related neurological conditions.The purpose of this registry is to collect long-term clinical information from patients with freezing of gait or gait and balance problems, and to explore how different causes of FOG are related to symptoms, walking patterns, falls, disease progression, and outcomes over time. The study will include participants with Parkinson's disease and other conditions associated with freezing of gait.Participants will receive standard medical care as determined by their treating physicians. No experimental drugs or study-related treatments will be assigned as part of this registry. Clinical information will be collected during routine visits and follow-up assessments, including questionnaires, walking and balance evaluations, video recordings, and other commonly used clinical tests.The information collected in this study may help improve the understanding of freezing of gait, support better risk assessment for falls, and guide future research and clinical management strategies for patients with gait and balance disorders.

Read the detailed description

Freezing of gait (FOG) is a common and disabling gait disturbance characterized by a transient inability to initiate or maintain effective stepping. It is most frequently observed in Parkinson's disease but can also occur in other parkinsonian syndromes and neurological conditions associated with gait and balance dysfunction. Freezing of gait is associated with falls, loss of independence, reduced quality of life, and increased caregiver burden, yet its underlying mechanisms, clinical heterogeneity, and long-term trajectories remain incompletely understood.

This study is a prospective, multicenter, observational patient registry designed to systematically collect longitudinal clinical data from adults with freezing of gait, gait and balance impairment, or those at high risk for developing freezing of gait. Participants will be recruited from neurology and related specialty clinics at participating centers and followed over time as part of routine clinical care.

The registry will collect a broad range of clinical information, including but not limited to:

Demographic and clinical characteristics; Freezing of gait severity and related symptoms; Objective gait parameters and balance performance assessed using standardized gait tasks; Motor symptom severity and functional status; Falls and fall-related outcomes; Health-related quality of life and other patient-reported outcomes. Clinical assessments will be performed at baseline and during scheduled follow-up visits over a planned follow-up period of up to 36 months. Data collection may include questionnaires, clinician-rated scales, objective gait and balance assessments, and video-based evaluations, depending on local clinical practice and participant capability.

This registry is non-interventional. All diagnostic and therapeutic decisions, including medication adjustments and rehabilitative interventions, will be made solely by the treating physicians according to standard clinical practice. The study does not mandate any experimental drugs, devices, or procedures.

The primary objectives of this registry are to:

Characterize the longitudinal course and clinical variability of freezing of gait; Examine associations between freezing of gait, gait and balance impairment, falls, and clinical outcomes; Identify potential clinical phenotypes and risk factors associated with worsening gait dysfunction and adverse outcomes.

The findings from this registry are intended to support hypothesis generation, improve clinical risk assessment, and provide a foundation for the development of future mechanistic studies and interventional trials targeting freezing of gait and related gait disorders.

03

Conditions studied

  • Freezing of Gait
  • Parkinson's Disease
  • Parkinsonism
  • Vascular Parkinsonism
  • Idiopathic Normal Pressure Hydrocephalus (INPH)

Keywords

  • Freezing of Gait
  • Parkinson's Disease
  • parkinsonism
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adults aged 30 to 85 years with freezing of gait or gait and balance impairment. Participants are diagnosed with Parkinson's disease or other parkinsonian or related neurological disorders associated with freezing of gait, including but not limited to parkinsonian syndromes and other causes of gait dysfunction.

Both participants with established freezing of gait and participants at high risk for developing freezing of gait are included. All participants are recruited from neurology and related specialty clinics at participating centers and are followed longitudinally as part of a prospective observational patient registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 30-85 years
  2. Presence of freezing of gait or non-freezing gait or balance impairment
  3. Diagnosis of Parkinson's disease or related parkinsonian disorders according to established international criteria (including PD, PSP, MSA, DLB, CBD, vascular parkinsonism, or idiopathic normal pressure hydrocephalus)
  4. Ability to complete gait and balance assessment tasks independently or with assistance
  5. Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  1. Severe dementia ( score \< 10)
  2. Severe psychiatric disorders interfering with study participation
  3. Severe cardiopulmonary, musculoskeletal, or other medical conditions significantly affecting gait safety
  4. Stroke, fracture, or other major medical events within the past 3 months
  5. Inability to comply with follow-up procedures
  6. Refusal of video or speech data collection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Target follow-up
36 Months
Patient registry
Yes

Groups and cohorts

  • FOG Group

    This cohort includes participants with freezing of gait present at baseline. Participants may have Parkinson's disease or other neurological conditions associated with freezing of gait. All participants receive standard clinical care as determined by their treating physicians. No experimental treatments or study-specific interventions are assigned as part of this observational registry.

    Other: Observational Data Collection

  • High-Risk Group

    This cohort includes participants with gait or balance impairment who have not developed freezing of gait at baseline but are considered at high risk for future freezing of gait. Participants may have Parkinson's disease or related neurological disorders. All participants receive standard clinical care, and no experimental treatments or study-specific interventions are provided as part of this observational registry.

    Other: Observational Data Collection

Interventions

  • OtherObservational Data Collection

    This is an observational patient registry. No experimental drugs, devices, or procedures are assigned as part of the study. All participants receive standard medical care, and data are collected during routine clinical visits and follow-up assessments.

06

What researchers measure

Primary outcomes

  1. Change in Freezing of Gait Severity Measured by the New Freezing of Gait Questionnaire (NFOG-Q)

    The New Freezing of Gait Questionnaire (NFOG-Q) is a patient-reported outcome measure assessing the severity and impact of freezing of gait in Parkinson's disease. The total score ranges from 0 to 28, with higher scores indicating more severe freezing of gait. The primary outcome is the change in NFOG-Q total score from baseline to 36 months.

    Time frame: Baseline to 36 months

Secondary outcomes

  1. Time to First Freezing of Gait Event

    Time from baseline to the first occurrence of freezing of gait in participants without freezing of gait at baseline.

    Time frame: Baseline to 36 months

  2. Frequency of Falls

    Number of falls reported during follow-up, collected through clinical visits and follow-up assessments.

    Time frame: Baseline to 36 months

  3. Change in Health-Related Quality of Life Measured by the Parkinson's Disease Questionnaire-39 (PDQ-39)

    Health-related quality of life will be assessed using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated patient-reported outcome measure for individuals with Parkinson's disease. The PDQ-39 Summary Index score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. The outcome is defined as the change in PDQ-39 Summary Index score from baseline to 36 months.

    Time frame: Baseline to 36 months

  4. Change in Gait Speed

    Gait speed will be measured during standardized gait tasks using an objective gait assessment system. The outcome is defined as the change in gait speed (meters per second, m/s) from baseline to 36 months, with higher values indicating better gait performance.

    Time frame: Baseline to 36 months

  5. Change in Stride Length

    Stride length will be assessed during standardized gait tasks using an objective gait assessment system. The outcome is defined as the change in stride length (meters, m) from baseline to 36 months, with higher values indicating better gait performance.

    Time frame: Baseline to 36 months

  6. Change in Gait Variability

    Gait variability will be quantified during standardized gait tasks using an objective gait assessment system. Gait variability will be expressed as the coefficient of variation (%) of stride length. The outcome is defined as the change in gait variability from baseline to 36 months, with lower values indicating better gait stability.

    Time frame: Baseline to 36 months

  7. Change in Balance Performance Measured by the Mini-Balance Evaluation Systems Test (Mini-BESTest)

    Balance performance will be assessed using the Mini-Balance Evaluation Systems Test (Mini-BESTest), a validated clinical scale for evaluating dynamic balance in patients with Parkinson's disease. The Mini-BESTest total score ranges from 0 to 28, with higher scores indicating better balance performance. The outcome is defined as the change in Mini-BESTest total score from baseline to 36 months.

    Time frame: Baseline to 36 months

  8. Changes in functional brain network connectivity assessed by resting-state functional MRI (fMRI)

    This outcome evaluates longitudinal changes in fMRI-derived functional connectivity within and between frontal cortical regions, basal ganglia, and brainstem locomotor control areas. The objective is to construct an integrated "brain network-clinical phenotype-FOG outcome" framework, enabling identification of neural network signatures specifically associated with freezing of gait and its progression.

    Time frame: Baseline to 36 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • 1.Talia H, Yael B, Michal B, et al.: A meta-analysis identifies factors predicting the future development of freezing of gait in parkinson's disease[J]. NPJ Parkinsons Dis 2023, 9.10.1038/s41531-023-00600-2. 2.Richard C, Meg E M, Frederico P-F, et al.: Prevention of falls in parkinson's disease: Guidelines and gaps[J]. Mov Disord Clin Pract 2023, 10.10.1002/mdc3.13860. 3.Seira T, Yuta K, Takanori K, et al.: New insights into freezing of gait in parkinson's disease from spectral dynamic causal modeling[J]. Mov Disord 2024, 39.10.1002/mds.29988. 4.Giladi N, Nieuwboer A. Understanding and treating freezing of gait in Parkinson's disease: a review of current concepts and future directions. Lancet Neurology. 2008;7(8):720-730. 5.Kelvin L C, Prabesh K, Miriam vEB, et al.: Cholinergic system changes in dopa-unresponsive freezing of gait in parkinson's disease[J]. Mov Disord 2025, 40.10.1002/mds.30196.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2029, 46 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 46 months is close to that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2025
First posted
Feb 4, 2026
StartActual
Feb 28, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Nov 30, 2030
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07386015
Lead sponsor
Tianjin Huanhu Hospital
Responsible party
Peipei Liu (Principal Investigator, Tianjin Huanhu Hospital) — Principal investigator
First posted
Feb 4, 2026
Start date
Feb 28, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Mar 10, 2026

Study contacts

Peipei Liu, MD
Contact
pddoctorpipi2021@163.com
86-13512204476
Peipei Liu, MD
principal investigator · Tianjin Huanhu Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion